Biological Products and Patent Challenges

As many biological products face losing their patents in the next decade, the pharmaceutical industry needs an abbreviated regulatory pathway for approval of biosimilar drug products, which are cost-effective, follow-on/subsequent versions of the innovator's biologic products.

Scientific Challenges

But scientific challenges remain due to the complexity of both the manuf